On May 18, 2022, Moderna and IAVI announced that the first participant screenings are soon to start for a Phase I clinical trial of an mRNA HIV vaccine antigen (mRNA-1644) at the Center for Family Health Research in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa.